Pittsburgh, PA (PRWEB) September 10, 2007
Keystone Therapeutics, Inc., which develops and implements services for clinical management and decision support to optimize drug therapy and reduce the incidence of medication errors, has just signed a two year agreement with Jefferson Regional Medical Center and Punxsutawney Area Hospital for the company's DoseResponse®Clinic anticoagulation management service.
"Our unique program for establishing and managing anticoagulation clinics helps physicians offices and hospitals establish a clinically superior and business efficient program that benefits patients, physicians and health systems. We achieve this by coupling our proprietary software, DoseResponse®, for infrastructure, documentation, management and reporting with our own team of specially trained Doctors of Pharmacy providing clinical management and oversight under protocols approved by the physicians and the organization," says Dr. Ray Stierer, Keystone's Director of Clinical Services.
DoseResponse® Clinics manage over 1,500 patients, use only 25 hours of a Pharm.D.'s time, and patients managed by the clinics average over 82 percent time in therapeutic range. "The physicians love the consistent patient management and real time reporting we provide on their patients, the patients love the clear and concise instruction and education on their therapy, and the hospitals and physician offices love the impact on patient safety and modest cost," says Mark Hudson, Vice President of Keystone Therapeutics.
There are currently between 2 and 4 million patients on warfarin (brand name Coumadin®) in the U.S., which is widely recognized as a difficult drug to manage. Current routine management of warfarin therapy is often viewed as costly, time consuming and risky by physicians, and established anticoagulation clinics, while more effective than routine management, are often burdened by high overhead costs. DoseResponse®Clinic provides consistent management adhering to a set of physician-approved national consensus guidelines and managed by Pharm .D.'s with specialty training in anticoagulation.
Newly released 2008 National Patient Safety Goals, published by the Joint Commission (http://www.jointcommission.org) include a requirement for hospitals, home care and long term care facilities to reduce the likelihood of patient harm due to anticoagulation therapy. "This new goal is causing hospitals and health systems to examine their current methods of anticoagulating patients, and many are realizing that DoseResponse®Clinic can quickly help them overcome the administrative, business, operational and clinical challenges they face in establishing a new clinic or expanding an existing clinic," says Mark Hudson.
The Joint Commission evaluates and accredits nearly 15,000 health care organizations and programs in the United States. An independent, not-for-profit organization, The Joint Commission is the nation's predominant standards-setting and accrediting body in health care.
Keystone Therapeutics, Inc. provides complete anticoagulation management solutions for clinics, physicians and health systems via DoseResponse®Clinic, a highly effective and efficient turnkey solution for offloading clinical management of warfarin patients and DoseResponse®, their flexible, reliable web-based software.
Keystone Therapeutics, Inc. provides their anticoagulation management tools and programs to over 90 hospitals, health care systems and physicians' offices in over 20 states.
For further information, contact Mark Hudson at 877.816.7912.
# # #